Three cardiac biomarkers and their efficacy: A review
Abstract
Objectives: This study belongs to the overview of three versatile cardiac biomarkers for specific diagnosis and prognosis in cardiac patients.
Methods: A search performed in different search sites such as Web of Science, Pub Med, and Google scholar searches for relevant studies from 2015 to 2022. Search names included were “heart disease,” “cardiac troponin,” “acute coronary disease,” “coronary artery disease,” “new biomarker,” “non–ST-elevation acute coronary syndrome,” etc. Studies were included if they were prospective, retrospective, randomized controlled trials or reviews.
Findings: Troponin I &T along with CPK-MB can increase the diagnostic sensitivity and specificity when used collectively in the diagnosis of Myocardial infarction either acute or chronic conditions. These cardiac versatile biomarkers can diagnose re-infarct also with serial testing. Whereas sensitivity and specificity of Troponins I &T ranges from 84 to 96 and 80 to 95% respectively. When all three cardiac markers were combined, sensitivity and specificity will reach up to approximately 100%.
Novelty/ Improvement: This article provides the best available three versatile specific cardiac biomarkers in the diagnosis of myocardial infarction and reinfarction with about 100% accuracy.
Keywords: Cardiovascular Disease (CVD), Myocardial Infarction (MI), Acute Myocardial Infarction (AMI), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), Heart type fatty acid binding protein (H-FABP).
Keywords:
Cardiovascular Disease (CVD), Myocardial Infarction (MI), Acute Myocardial Infarction (AMI), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), Heart type fatty acid binding protein (H-FABP)DOI
https://doi.org/10.22270/jddt.v12i4-S.5471References
Wu Yuling, Pan Nana, An Yi, Xu Mengyuan, Tan Lijuan, Zhang Lijuan. Diagnostic and Prognostic Biomarkers for Myocardial Infarction. Front. Cardiovasc. Med., 03 February 2021 | https://doi.org/10.3389/fcvm.2020.617277 https://www.frontiersin.org/articles/10.3389/fcvm.2020.617277/full
Aydin S, Ugur K, Aydin S, Sahin İ, Yardim M. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019;15:1-10. Published 2019 Jan 17. doi: https://doi.org/10.2147/VHRM.S166157 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340361/
Tilea, Ioan et al. “Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.” Diagnostics (Basel, Switzerland) 2021; 11(5):881, doi: https://doi.org/10.3390/diagnostics11050881 https://www.mdpi.com/2075-4418/11/5/881
Baran A, Kiluk P, Nowowiejska J, Kaminski TW, Maciaszek M, Flisiak I. Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment—Preliminary Data. Biology. 2022 Jan; 11(1):88./ https://www.mdpi.com/2079-7737/11/1/88 https://doi.org/10.3390/biology11010088
Kott, K.A.; Bishop, M.; Yang, C.H.J.; Plasto, T.M.; Cheng, D.C.; Kaplan, A.I.; Cullen, L.; Celermajer, D.S.; Meikle, P.J.; Vernon, S.T.; et al. Biomarker Development in Cardiology: Reviewing the Past to Inform the Future. Cells 2022, 11, 588. https://doi.org/10.3390/cells11030588 https://www.mdpi.com/2073-4409/11/3/588
Chen, Heng et al. “Cardiac Troponin I and Risk of Stroke: A Mendelian Randomization Study.” International journal of general medicine 2022; 15:1575-1582. doi: https://doi.org/10.2147IJGM.S351034 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858012/
Nils A Sörensen, Johannes T Neumann, Francisco Ojeda, Evangelos Giannitsis, Eberhard Spanuth, Stefan Blankenberg, Dirk Westermann, Tanja Zeller, Diagnostic Evaluation of a High-Sensitivity Troponin I Point-of-Care Assay, Clinical Chemistry, 2019; 65(12), Pages 1592–1601, https://doi.org/10.1373/clinchem.2019.307405 https://academic.oup.com/clinchem/article/65/12/1592/5715864?login=true
Published
Abstract Display: 1085 
PDF Downloads: 1148 PDF Downloads: 143 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.